Treatment of the acute leukemias.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D001215:Asparaginase / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007938:Leukemia / Q000276:immunology; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009163:Mycobacterium bovis / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001215:Asparaginase; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin